[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,873,410
  • Shares Outstanding, K 102,879
  • Annual Sales, $ 139,740 K
  • Annual Income, $ -79,990 K
  • EBIT $ -372 M
  • EBITDA $ -365 M
  • 60-Month Beta 2.26
  • Price/Sales 21.74
  • Price/Cash Flow N/A
  • Price/Book 2.61

Options Overview Details

View History
  • Implied Volatility 90.84% (+0.64%)
  • Historical Volatility 74.19%
  • IV Percentile 72%
  • IV Rank 54.63%
  • IV High 122.94% on 02/11/26
  • IV Low 52.20% on 08/06/25
  • Expected Move (DTE 32) 7.89 (28.24%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 976
  • Volume Avg (30-Day) 555
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 17,041
  • Open Int (30-Day) 14,501
  • Expected Range 20.04 to 35.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.03
  • Number of Estimates 6
  • High Estimate $-0.95
  • Low Estimate $-1.16
  • Prior Year $-1.00
  • Growth Rate Est. (year over year) -3.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.10 +3.06%
on 04/24/26
34.38 -18.75%
on 05/11/26
-2.75 (-8.96%)
since 04/15/26
3-Month
21.63 +29.13%
on 03/30/26
34.38 -18.75%
on 05/11/26
+0.01 (+0.04%)
since 02/13/26
52-Week
15.35 +81.95%
on 05/30/25
36.44 -23.35%
on 01/12/26
+10.68 (+61.91%)
since 05/15/25

Most Recent Stories

More News
Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.

BEAM : 27.93 (-5.42%)
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...

BEAM : 27.93 (-5.42%)
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...

BEAM : 27.93 (-5.42%)
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected...

BEAM : 27.93 (-5.42%)
Beam Therapeutics Reports Tomorrow, but the Pipeline Questions Linger Louder Than Ever

Barchart Research What to Expect from BEAM Earnings BEAM Generated May 4, 2026 Current Price $30.08 EPS Estimate $$-0.87 Consensus Rating Strong Buy Average Move 6.00% Beam Therapeutics Reports Tomorrow,...

BEAM : 27.93 (-5.42%)
3 Biotech Stocks That Could Benefit from the Patent Cliff

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets

BEAM : 27.93 (-5.42%)
CRSP : 48.41 (-4.04%)
MRK : 111.38 (-1.79%)
BMY : 57.00 (+0.41%)
NTLA : 13.67 (+4.43%)
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31...

BEAM : 27.93 (-5.42%)
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up...

BEAM : 27.93 (-5.42%)
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and...

BEAM : 27.93 (-5.42%)
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated...

BEAM : 27.93 (-5.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 30.55
2nd Resistance Point 29.94
1st Resistance Point 28.94
Last Price 27.93
1st Support Level 27.33
2nd Support Level 26.72
3rd Support Level 25.72

See More

52-Week High 36.44
Fibonacci 61.8% 28.38
Last Price 27.93
Fibonacci 50% 25.90
Fibonacci 38.2% 23.41
52-Week Low 15.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.